Mannkind Afrezza FDA Panel Live Blog

 
Welcome to the Mannkind ( MNKD) Afrezza FDA Panel live blog.

The FDA has gathered a group of medical experts together today to review and discuss Afrezza, an inhaled, rapid-acting insulin designed for the treatment of Type 1 and Type 2 diabetes. At the end of today's all-day meeting, the experts will vote on whether or not to recommend Afrezza's approval. 

This is Mannkind's third attempt at getting Afrezza approved. The FDA rejected the product both times previously. For this resubmission, Mannkind conducted two phase III studies of Afrezza, one each in Type 1 and Type 2 diabetes. 

TheStreet's biotech columnist Adam Feuerstein published a preview of today's panel on Monday

Follow along all the action today as Feuerstein live blogs the Afrezza panel.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

10 Key Takeaways From Google's Solid Earnings Report

10 Key Takeaways From Google's Solid Earnings Report

Wait, Google Was Almost Called What?

Wait, Google Was Almost Called What?

M&A Overshadows Telecom Earnings, DOJ eSIM Card Inquiry

M&A Overshadows Telecom Earnings, DOJ eSIM Card Inquiry

Amazon Is as Well-Positioned as Anyone to Create a Popular Home Robot

Amazon Is as Well-Positioned as Anyone to Create a Popular Home Robot

Bitcoin Today: Prices Flirt With $9,000 After Weekend Boom

Bitcoin Today: Prices Flirt With $9,000 After Weekend Boom